St. Jude Study Reveals Key Immune Differences Between RSV and SARS-CoV-2 in Infants
Event summary
- St. Jude and The Jackson Laboratory published a study in Science Translational Medicine on February 25, 2026, revealing differing immune responses in infants to RSV and SARS-CoV-2.
- The study found that RSV triggers lower systemic inflammation and a poorly coordinated early immune response, primarily involving natural killer cells, compared to SARS-CoV-2.
- RSV was linked to fewer natural killer cells and lower interferon-gamma expression, which correlated with disease severity.
- The research suggests that anti-inflammatory treatments like steroids may be harmful for infants with RSV due to its immunosuppressive nature.
- The study analyzed immune responses from 19 infants with RSV, 30 with SARS-CoV-2, and 17 healthy infants, most around 2 months old.
The big picture
The study highlights the critical differences in immune responses to RSV and SARS-CoV-2, which could reshape treatment strategies for infant respiratory infections. RSV remains a leading cause of infant hospitalizations and mortality, making this research pivotal for global health efforts. The findings underscore the need for tailored therapeutic approaches based on the specific immune dysregulation caused by each virus.
What we're watching
- Treatment Implications
- How the findings will influence clinical guidelines for treating RSV in infants, particularly the avoidance of steroids.
- Future Research
- Whether the epigenetic reprogramming observed in RSV infections will impact long-term immune responses in infants.
- Global Health Impact
- The pace at which these insights can be translated into improved outcomes for the millions of children who die from infections before the age of 5.
Related topics